mAbxience, partly owned by Fresenius Kabi and Insud Pharma, has entered a strategic agreement with Egis Pharmaceutical PLC to commercialise two biosimilar candidates in Central and Eastern Europe. The partnership encompasses eight countries: Hungary, Poland, Czech Republic, Slovakia, Romania, Bulgaria,
mAbxience, a company in the pharmaceutical industry, has announced the appointment of Jurgen Van Broeck as its new Chief Executive Officer. Broeck, who has been serving as the Global Commercial Director since June 2023, is set to bring his wealth
Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd., and mAbxience, a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma, have announced a strategic licensing agreement for a biosimilar candidate currently in development for the treatment
mAbxience is a Pharmaceutical company, CMO/CDMO, Biopharmaceutical company, Contract Research Organisation (CRO), Generics/Biosimilars Manufacturer company operating in the pharmaceutical industry. mAbxience is a global biotech company dedicated to the development and manufacture of biologics, supporting access to high-quality medicines. We
Stay ahead of trends and best practices
Exclusive downloads and podcasts
Get invites to special events and meetups 
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
